MAPT and Alzheimer disease: To date, only one other anti-Tau active immunotherapy, AADvac1, comprising tau peptide 294–305/4R coupled to Keyhole Limpet Haemocyanin and formulated with aluminium hydroxide, has published Phase 2 clinical data, in 196 participants with mild AD.